CSIMarket
 
Vaccinex Inc   (VCNX)
 

Vaccinex Inc released Revenue of $0.85 million, in the fiscal span ending December 31 2022

VCNX reported fourth quarter of 2022 operating shortfall of $-7.703 million


Published Apr 02 2023
CSIMarket Team / CSIMarket.com


Autosample_takes_a_By_Hey_Paul_(originally_posted_to_Flickr_as_image4)_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons the Major Pharmaceutical Preparations company proclaimed $0.85 million, in Revenue in the fourth quarter of 2022.




For the fourth quarter of 2022 Vaccinex Inc realized net shortfall of $-7.643 million, higher than $-4.631 million a year ago.

Furthermore, the Vaccinex Inc noted also a shortfall of $-22.38 million and for the fiscal period 2021, revenue of $0.90 million.

Major Pharmaceutical Preparations Vaccinex Inc has decreased it's shortfall per share to $-0.78 from $-1.54 in the prior fiscal year, while revenue surged by 44 % from $0.63 million a year prior.

Vaccinex Inc is expected to report next financial earnings on May 15, 2023.



Vaccinex Inc's Net Income Growth

Vaccinex Inc's Operating Margin



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com